Mehmet DEMİR, Ümit YILMAZ, Cemil ÇOLAK, Yılmaz ÇİĞREMİŞ, Fatma ÖZYALIN, İbrahim TEKEDERELİ, Ayten KILINÇLI, Süleyman SANDAL

The effects of lack of melatonin in experimental rat model of Alzheimer’s Disease: relationship with FEZ1 gene expression

Alzheimer’s Disease (AD), which is the most common reason for dementia, is an irreversible neurodegenerative brain disease. FEZ1 is a protein expressed in the brain. High expressions of FEZ1 mRNA have been interpreted as an indicator of high neural plasticity for memory and learning. This study was planned to determine the effect of melatonin deficiency (pinealectomy; PnX) on AD and to reveal its association with FEZ1. 30 male rats were used in the study. The rats were divided into three as SHAM, PnX+streptozotocin (STZ) and PnX+STZ+melatonin (MLT) groups. The pineal glands of rats were surgically removed (except SHAM group) and STZ was intracerebroventricularly (icv) administrated at the first and third days. MLT (10 mg/kg/day) was intraperitoneally (ip) injected 1 h before the first STZ application and it was continued for 14 days. STZ and MLT solvents were applied to the rats in the SHAM group. At the end of the applications, Morris water maze (MWM) test was carried out the rats. At the end of MWM tests, the rats were sacrificed and their blood and hippocampus tissues were taken. FEZ1 gene expression and protein levels were determined from hippocampus tissue, while serum nonadrenaline, dopamine and serotonin levels were detected from blood samples. FEZ1 protein levels of PnX+STZ+MLT group were found to be statistically significantly lower than those of SHAM and PnX+STZ groups (p

PDF

___

1. Rodriguez-Perdigon M, Tordera RM, Gil-Bea FJ, Gerenu G, Ramirez MJ, Solas M. Down-regulation of glutamatergic terminals (VGLUT1) driven by Abeta in Alzheimer's disease. Hippocampus. 2016;26(10):1303-12.

2. Lee JS, Kim JY, Kim HJ, Kim JC, Lee JS, Kim N, Park MJ. Effects of combined radiofrequency field exposure on amyloid-beta-induced cytotoxicity in HT22 mouse hippocampal neurones. J Radiat Res. 2016;20 [Epub ahead of print].

3. Pouryamout L, Dams J, Wasem J, Dodel R, Neumann A. Economic evaluation of treatment options in patients with Alzheimer's disease: a systematic review of cost-effectiveness analyses. Drugs. 2012;72(6):789-802.

4. Bolognin S, Blanchard J, Wang X, Basurto-Islas G, Tung YC, Kohlbrenner E, Grundke-Iqbal I, Iqbal K. An experimental rat model of sporadic Alzheimer's disease and rescue of cognitive impairment with a neurotrophic peptide. Acta neuropathol. 2012;123(1):133-51.

5. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci USA. 1986;83(13):4913-7.

6. Pickett EK, Koffie RM, Wegmann S, Henstridge CM, Herrmann AG, Colom-Cadena M, Lleo A, Kay KR, Vaught M, Soberman R, Walsh DM, Hyman BT, Spires-Jones TL. Non-Fibrillar Oligomeric Amyloid-beta within Synapses. J Alzheimers Dis. 2016;53(3):787- 800.

7. Zheng H, Koo EH. Biology and pathophysiology of the amyloid precursor protein. Mol Neurodegener. 2011;6(1):27.

8. Loureiro JA, Rocha S, Pereira Mdo C. Charged surfactants induce a non-fibrillar aggregation pathway of amyloid-beta peptide. J Pept Sci. 2013;19(9):581-7.

9. Yang X, Sun GY, Eckert GP, Lee JC. Cellular membrane fluidity in amyloid precursor protein processing. Mol Neurobiol. 2014;50(1):119-29.

10. Zambrano N, Gianni D, Bruni P, Passaro F, Telese F, Russo T. Fe65 is not involved in the platelet-derived growth factor-induced processing of Alzheimer's amyloid precursor protein, which activates its caspase-directed cleavage. J Biol Chem. 2004;279(16):16161-9.

11. Piao Y, Kimura A, Urano S, Saito Y, Taru H, Yamamoto T, Hata S, Suzuki T. Mechanism of intramembrane cleavage of alcadeins by gamma-secretase. PloS one. 2013;8(4):e62431.

12. Kowalska A. The beta-amyloid cascade hypothesis: a sequence of events leading to neurodegeneration in Alzheimer's disease. Neurol Neurochir Pol. 2004;38(5):405-11.

13. Naslund J, Jensen M, Tjernberg LO, Thyberg J, Terenius L, Nordstedt C. The metabolic pathway generating p3, an A betapeptide fragment, is probably non-amyloidogenic. Biochem Biophys Res Commun. 1994;204(2):780-7.

14. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta neuropathol. 1991;82(4):239-59.

15. Cowan CM, Chee F, Shepherd D, Mudher A. Disruption of neuronal function by soluble hyperphosphorylated tau in a Drosophila model of tauopathy. Biochem Soc Trans. 2010;38(2):564-70.

16. Fujita T, Ikuta J, Hamada J, Okajima T, Tatematsu K, Tanizawa K, Kuroda S. Identification of a tissue-non-specific homologue of axonal fasciculation and elongation protein zeta-1. Biochem Biophys Res Commun. 2004;313(3):738-44.

17. Kuroda S, Nakagawa N, Tokunaga C, Tatematsu K, Tanizawa K. Mammalian homologue of the Caenorhabditis elegans UNC-76 protein involved in axonal outgrowth is a protein kinase C zetainteracting protein. J Cell Biol. 1999;144(3):403-11.

18. Ikuta J, Maturana A, Fujita T, Okajima T, Tatematsu K, Tanizawa K, Kuroda S. Fasciculation and elongation protein zeta-1 (FEZ1) participates in the polarization of hippocampal neuron by controlling the mitochondrial motility. Biochem Biophys Res Commun. 2007;353(1):127-32.

19. Maturana AD, Fujita T, Kuroda S. Functions of fasciculation and elongation protein zeta-1 (FEZ1) in the brain. Scientific World Journal. 2010;10:1646-54.

20. Inoue K, Terashima T, Nishikawa T, Takumi T. Fez1 is layerspecifically expressed in the adult mouse neocortex. Eur J Neurosci. 2004;20(11):2909-16.

21. Su B, Wang X, Zheng L, Perry G, Smith MA, Zhu X. Abnormal mitochondrial dynamics and neurodegenerative diseases. Biochim Biophys Acta. 2010;1802(1):135-42.

22. Chen JX, Yan SD. Amyloid-beta-induced mitochondrial dysfunction. J Alzheimers Dis. 2007;12(2):177-84.

23. Benitez-King G. Melatonin as a cytoskeletal modulator: implications for cell physiology and disease. J Pineal Res. 2006;40(1):1-9.

24. Ionov M, Burchell V, Klajnert B, Bryszewska M, Abramov AY. Mechanism of neuroprotection of melatonin against beta-amyloid neurotoxicity. Neuroscience. 2011;180:229-37.

25. Srinivasan V, Pandi-Perumal SR, Maestroni GJ, Esquifino AI, Hardeland R, Cardinali DP. Role of melatonin in neurodegenerative diseases. Neurotox Res. 2005;7(4):293-318.

26. Sachdeva AK, Kuhad A, Chopra K. Naringin ameliorates memory deficits in experimental paradigm of Alzheimer's disease by attenuating mitochondrial dysfunction. Pharmacol Biochem Behav. 2014;127:101-10.

27. Salkovic-Petrisic M, Hoyer S. Central insulin resistance as a trigger for sporadic Alzheimer-like pathology: an experimental approach. J Neural Transm Suppl. 2007(72):217-33.

28. Kumar A, Sharma S, Prashar A, Deshmukh R. Effect of licofelone--a dual COX/5-LOX inhibitor in intracerebroventricular streptozotocininduced behavioral and biochemical abnormalities in rats. J Mol Neurosci: MN. 2015;55(3):749-59.

29. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates , 7th Edition. London, UK: Academic Press; 2013.

30. Agrawal R, Tyagi E, Shukla R, Nath C. Insulin receptor signaling in rat hippocampus: a study in STZ (ICV) induced memory deficit model. Eur Neuropsychopharmacol. 2011;21(3):261-73.

31. Gwayi N, Bernard RT. The effects of melatonin on sperm motility in vitro in Wistar rats. Andrologia. 2002;34(6):391-6.

32. Matsubara E, Bryant-Thomas T, Pacheco Quinto J, Henry TL, Poeggeler B, Herbert D, Cruz-Sanchez F, Chyan YJ, Smith MA, Perry G, Shoji M, Abe K, Leone A, Grundke-Ikbal I, Wilson GL, Ghiso J, Williams C, Refolo LM, Pappolla MA, Chain DG, Neria E. Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer's disease. J Neurochem. 2003;85(5):1101-8.

33. Saxena G, Bharti S, Kamat PK, Sharma S, Nath C. Melatonin alleviates memory deficits and neuronal degeneration induced by intracerebroventricular administration of streptozotocin in rats. Pharmacol Biochem Behav. 2010;94(3):397-403 . 34. Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods. 1984;11(1):47-60.

35. Elcioglu H, Kabasakal L, Alan S, Salva E, Tufan F, Karan M. Thalidomide attenuates learning and memory deficits induced by intracerebroventricular administration of streptozotocin in rats. Biotech Histochem. 2013;88(3-4):145-52.

36. Tota S, Kamat PK, Saxena G, Hanif K, Najmi AK, Nath C. Central angiotensin converting enzyme facilitates memory impairment in intracerebroventricular streptozotocin treated rats. Behav Brain Res. 2012;226(1):317-30.

37. Tiwari V, Kuhad A, Bishnoi M, Chopra K. Chronic treatment with tocotrienol, an isoform of vitamin E, prevents intracerebroventricular streptozotocin-induced cognitive impairment and oxidativenitrosative stress in rats. Pharmacol Biochem Behav. 2009;93(2):183- 9.

38. Chen S, Liu AR, An FM, Yao WB, Gao XD. Amelioration of neurodegenerative changes in cellular and rat models of diabetesrelated Alzheimer's disease by exendin-4. Age. 2012;34(5):1211-24.

39. Wu YH, Fischer DF, Swaab DF. A promoter polymorphism in the monoamine oxidase A gene is associated with the pineal MAOA activity in Alzheimer's disease patients. Brain Res. 2007;1167:13-9.

40. Wang XC, Zhang J, Yu X, Han L, Zhou ZT, Zhang Y, Wang JZ. Prevention of isoproterenol-induced tau hyperphosphorylation by melatonin in the rat. Sheng Li Xue Bao. 2005;57(1):7-12.

41. Pierpaoli W, Maestroni GJ. Melatonin: a principal neuroimmunoregulatory and anti-stress hormone: its anti-aging effects. Immunol Lett. 1987;16(3-4):355-61.

42. Pierpaoli W, Yi C. The involvement of pineal gland and melatonin in immunity and aging. I. Thymus-mediated, immunoreconstituting and antiviral activity of thyrotropin-releasing hormone. J Neuroimmunol. 1990;27(2-3):99-109.

43. Dong W, Huang F, Fan W, Cheng S, Chen Y, Zhang W, Shi H, He H. Differential effects of melatonin on amyloid-beta peptide 25-35- induced mitochondrial dysfunction in hippocampal neurons at different stages of culture. J Pineal Res. 2010;48(2):117-25.

44. Quinn J, Kulhanek D, Nowlin J, Jones R, Pratico D, Rokach J, Stackman R. Chronic melatonin therapy fails to alter amyloid burden or oxidative damage in old Tg2576 mice: implications for clinical trials. Brain Res. 2005;1037(1-2):209-13.

45. Feng Z, Qin C, Chang Y, Zhang JT. Early melatonin supplementation alleviates oxidative stress in a transgenic mouse model of Alzheimer's disease. Free Radic Biol Med. 2006;40(1):101-9.

46. Wang JZ, Wang ZF. Role of melatonin in Alzheimer-like neurodegeneration. Acta Pharmacol Sin. 2006;27(1):41-9.

47. Cheng Y, Feng Z, Zhang QZ, Zhang JT. Beneficial effects of melatonin in experimental models of Alzheimer disease. Acta Pharmacol Sin. 2006;27(2):129-39.

48. Shahpasand K, Uemura I, Saito T, Asano T, Hata K, Shibata K, Toyoshima Y, Hasegawa M, Hisanaga S. Regulation of mitochondrial transport and inter-microtubule spacing by tau phosphorylation at the sites hyperphosphorylated in Alzheimer's disease. J Neurosci. 2012;32(7):2430-41.

49. Gennerich A, Vale RD. Walking the walk: how kinesin and dynein coordinate their steps. Curr Opin Cell Bio. 2009;21(1):59-67.

50. Toda H, Mochizuki H, Flores R 3rd, Josowitz R, Krasieva TB, Lamorte VJ, Suzuki E, Gindhart JG, Furukubo-Tokunaga K, Tomoda T. UNC-51/ATG1 kinase regulates axonal transport by mediating motor-cargo assembly. Genes Dev. 2008;22(23):3292-307.

51. Blasius TL, Cai D, Jih GT, Toret CP, Verhey KJ. Two binding partners cooperate to activate the molecular motor Kinesin-1. J Cell Biol. 2007;176(1):11-7.

52. Fujita T, Maturana AD, Ikuta J, Hamada J, Walchli S, Suzuki T, et al. Axonal guidance protein FEZ1 associates with tubulin and kinesin motor protein to transport mitochondria in neurites of NGFstimulated PC12 cells. Biochem Biophys Res Commun. 2007;361(3):605-10.